RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

the most promising on that list is CX 1942. Its application is narrow, and addresses a priority issue (opioid-induced RD). This may be the easiest compound to bring into the clinic, and would generate revenue. This isn't really an application in which an illness is being treated, the drug is being administered to mitigate an undesirable side-effect of another necessary drug. To my mind, this is a more straight-forward proposition.

The SA is a much heavier lift, and a much more complicated indication.